This grant will provide support for the Statistics and Data Management Center (SDMC) of the ECOG- ACRIN Cancer Research Group. The SDMC is organized and operated jointly by the Department of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute (DFCI), the Department of Biostatistics at Brown University, the ECOG-ACRIN Medical Research Foundation (EAMRF), and the American College of Radiology (ACR), under the direction of the Group Statisticians. The primary responsibility for data collection and management belongs to the Data Management Center, consisting of EAMRF and ACR. The primary responsibility for study design, monitoring, and analysis, and for overseeing and coordinating SDMC operations, belongs to the Biostatistics Center, consisting of DFCI and Brown University. The primary contact site for grant administration is DFCI. ECOG-ACRIN is a multi-modality group conducting a wide range of studies, including definitive phase III trials of therapeutic interventions, earlier phase studies developing new therapies, studies focused on diagnosis and of advanced imaging methods, investigation of laboratory and imaging based biomarkers, and studies incorporating patient reported outcomes. The SDMC is responsible for all quantitative aspects of EA's activities. Our overall goals are to conduct clinical trials to the highest standards in statistical methods, data management, and regulatory compliance, while continually improving efficiency of all of our processes and systems to optimize the use of our limited resources. Areas of particular focus in this grant include studies incorporating tissue and imaging biomarkers to direct therapy, studies of immunotherapy, studies of de-intensification of therapy to reduce morbidity, studies investigating novel biomarkers, and studies investigating the relationship of biomarkers and therapy in populations defined by race, ethnicity, gender, and age.

Public Health Relevance

The overall purpose of this grant is to provide expertise in statistics and data management to support the research mission of the ECOG-ACRIN Cancer Research Group. Achievement of our objectives will enable ECOG-ACRIN to continue to produce high quality clinical studies that advance the care of cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA180794-07
Application #
9906857
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
2014-04-29
Project End
2025-02-28
Budget Start
2020-03-01
Budget End
2021-02-28
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Wong, Yu-Ning; Manola, Judith; Hudes, Gary R et al. (2018) Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial. Clin Genitourin Cancer 16:e315-e322
Scott, David W; King, Rebecca L; Staiger, Annette M et al. (2018) High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood 131:2060-2064
Ailawadhi, Sikander; Jacobus, Susanna; Sexton, Rachael et al. (2018) Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 8:67
Morgans, Alicia K; Chen, Yu-Hui; Sweeney, Christopher J et al. (2018) Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. J Clin Oncol 36:1088-1095
Tarhini, Ahmad A; Lee, Sandra J; Li, Xiaoxue et al. (2018) E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-?2b in Advanced Melanoma. Clin Cancer Res :
Lubner, Sam; Feng, Yang; Mulcahy, Mary et al. (2018) E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist 23:1006-e104
Ratai, Eva-Maria; Zhang, Zheng; Fink, James et al. (2018) ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy. PLoS One 13:e0198548
King, Rebecca L; Nowakowski, Grzegorz S; Witzig, Thomas E et al. (2018) Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. Blood Cancer J 8:27
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903

Showing the most recent 10 out of 187 publications